Dr. Chawla is currently the CMO at Exthera Medical and the President of the Stavro Division. Previously, Dr. Chawla was the CEO of Stavro Medical which was acquired by Exthera Medical in April of 2024. 2020-2023 - CMO at Silver Creek Pharma where he oversaw the Phase 2 development of scp776. 2015-2020 - CMO of La Jolla Pharmaceutical Company. While he was at LJPC, he oversaw the development and conduct of the Phase 3 ATHOS-3 trial. 2003-2015 - Faculty at the George Washington University and attained the rank of Professor of Medicine. There, he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla was previously the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. During his tenure at George Washington, Dr. Chawla was the designer and lead investigator of a pilot study called the ATHOS (Angiotensin II for the Treatment of High Output Shock) trial. Data from the ATHOS trial was published in the medical journal Critical Care during 2014 and these data were also used in support of the initiation of La Jolla’s ATHOS 3 trial, a Phase 3 clinical trial of LJPC-501, LJPC’s formulation of angiotensin II, for the treatment of catecholamine-resistant hypotension. The data from the ATHOS-3 Trial helped support the FDA approval of GIAPREZA(angiotensin II) on December 21, 2017 and EMA approval in August 2019. Thereafter, Dr. Chawla oversaw the Medical Affairs launch and commercialization of GIAPREZA. Dr. Chawla is an internationally renowned expert in the field of acute kidney injury (AKI) and shock. He remains an active investigator in the fields of AKI biomarkers, AKI risk prediction, AKI therapeutics and chronic kidney disease caused by AKI. Dr. Chawla is also the author of over 170 peer-reviewed publications and a recipient of the International Vicenza Award for Critical Care Nephrology; an award that recognizes individuals who have made seminal clinical research advancements that have significantly improved the care of critically ill patients with AKI and have been adopted worldwide